Latest Kaiser Health News Stories
Alec Raeshawn Smith was 23 when diagnosed with Type 1 diabetes, and 26 when he died. He couldn’t afford $1,300 per month for his insulin and other diabetes supplies. So he tried to stretch the doses.
Desperate for help in finding a lifesaving drug for a fatal genetic disease, families banded together to fund early research and then worked with drug companies on clinical trials and marketing. Yet, this small patient advocacy group is stunned by pharma’s pricing.
California legislators approved some significant health care proposals in their rush to meet the Friday end-of-session deadline. They tackled controversial topics, such as making abortion pills available on college campuses, and adopted measures countering Trump administration attacks on the Affordable Care Act.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico answer listeners’ questions about health policy and politics.
Instead of waiting for congressional action, federal regulators are looking at a series of actions to spur competition and drive down the cost of medicines.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Margot Sanger-Katz of The New York Times and Kimberly Leonard of the Washington Examiner talk about the latest Trump administration efforts to address high drug prices, what’s next for short-term health insurance plans and insider trading charges against a New York GOP congressman.
Inspector general identifies possible problems in nearly 23 percent of pharmacies that bill Medicare for blended creams, gels and lotions.
The number of diabetes drug prescriptions filled for low-income people enrolled in Medicaid rose sharply in states that expanded eligibility for the program under the Affordable Care Act, according to a new study.
The Trump administration signals it is willing to consider such a move if it is carefully tailored to focus solely on specific situations where a high-priced drug is made by one company.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Alice Ollstein of Talking Points Memo and Kimberly Leonard of the Washington Examiner talk about the new push on health legislation by Republicans in the House, as well as developments on Medicaid work requirements, drug prices and the fate of children separated from their parents at the U.S.-Mexican border. Plus, for extra credit, the panelists offer their favorite health stories of the week.
Several major drugmakers vow to contain drug prices, but similar pledges since the 1990s have not had much impact.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico, and Erin Mershon of Stat News discuss a series of health policy court decisions on everything from prescription drug discounts to soda taxes. Plus, Rovner, interviews health care futurist and consultant Jeff Goldsmith.
Some state Medicaid programs are not paying for the procedures, and Medicare’s complicated payment rates have hospitals concerned that it will not cover all the costs.
The vaccine, BCG, is relatively cheap. But experts caution the therapy could be overhyped and, if proven effective, wind up overpriced.